Rie Shiokawa

First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer

Sarah P. Blagden, Aurelius Olmin, Debra H. Josephs et al. · Clinical Cancer Research · 2014 · 47 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14

An orally active motilin receptor antagonist, MA-2029, inhibits motilin-induced gastrointestinal motility, increase in fundic tone, and diarrhea in conscious dogs without affecting gastric emptying

Kenichi Ozaki, Mitsu Onoma, Hiroyasu Muramatsu et al. · European Journal of Pharmacology · 2009 · 33 citations

Medicine, Pharmacology, Veterinary Physiology +15

Antigen-Dependent Internalization Is Related to Rapid Elimination from Plasma of Humanized Anti-HM1.24 Monoclonal Antibody

Jun Amano, Naoko Masuyama, Yuko Hirota et al. · Drug Metabolism and Disposition · 2010 · 16 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Analysis of in Vitro Skin Permeation of 22-Oxacalcitriol Having a Complicated Metabolic Pathway

Koji Yamaguchi, T Mitsui, Toshinori Yamamoto et al. · Pharmaceutical Research · 2006 · 13 citations

Pharmacy, Pharmacokinetics, Pharmacology +11